opnMe News

Let´s live innovation. Want to know the latest news and trends? Read more

Subscribe to our newsletter to stay up to date with latest developments

Latest news

Launch of the third opnMe challenge in 2019: Unlock the full potential of our potent & selective SOS1::KRAS inhibitor as part of a scientific collaboration. Apply now!

9 September 2019

As an expert in your field, you may be excited to learn that Boehringer Ingelheim is now seeking novel applications for its unprecedented, potent and highly selective orally bioavailable SOS1::KRAS inhibitor BI-3406.

SOS1::KRAS Protein-Protein Interaction (PPI) inhibitor News Announcement

With BI-2852 we have added a potent KRAS switch I/II pocket inhibitor which inhibits both active & inactive forms of KRAS – Order now for free on opnMe!
up
27

22 July 2019

In parallel to a publication in the Proceedings of the National Academy of Sciences (PNAS)1BI-2852, a potent and selective in vitro tool to investigate KRAS signaling has been made available free of charge on opnMe.com. BI-2852 targets a part of the KRAS protein which has been previously considered “undruggable” and hence represents a novel approach to interfere with the KRAS signaling pathway. KRAS is predicted to have roles in many human diseases with high unmet medical need such as cancer indications & beyond.

Complex of KRAS bound to BI-2852

Order for free today: With BI-3663 and BI-0319 we release two new highly selective PTK2 PROTACs (proteolysis targeting chimeras) to opnMe.com
up
36

9 July 2019

Targeted protein degradation by exploiting the ubiquitin proteasome system has recently emerged as a new and promising modality of intervention in drug discovery. One approach to induce protein degradation is to design hetero bifunctional molecules called proteolysis-targeting chimeras – also known as PROTACs. In combination with structure-based drug design, it has allowed researchers to aim at new targets which were previously deemed “undruggable”.

With BI-3663 and BI-0319 we release two new highly selective PTK2 PROTACs

Congratulations to the winner of our 2nd opnMe poll: NMDA receptor antagonist BIII 277CL has received the majority of all votes and has been launched today. Access it now for free!
up
55

18 May 2019

Today, Boehringer Ingelheim has added its well-characterized non-covalent ATP-competitive receptor channel complex (glycine and NMDA binding sites) BIII 277CL to its molecule platform opnMe.com. High selectivity and decent PK properties make BIII 277CL a suitable tool for in vivo validation of NMDA as a therapeutic target.

The winner is NMDA

Order for free today. In connection with the 2nd International Symposium on Cathepsin C we will release three new Cathepsin C molecules on opnMe.com: BI-9740, BI-1750, and BI-2051
up
59

17 April 2019

In connection with the 2nd International Symposium on Cathepsin C we have launched today the first of three new Cathepsin C molecules on opnMe.com. These will be featured as part of a talk provided by Marc Grundl, Senior Principal Scientist, Medicinal Chemistry, Boehringer Ingelheim with the title: “Cathepsin C: a challenge for medicinal chemistry”.

BI-9740, 3-D conformation co-crystalized in the Cathepsin C protein

Collaborate now with our scientists to pursue your novel disease hypothesis for our oral BCL6 degrader
up
51

15 April 2019

As an expert in your field, you may be excited to learn that Boehringer Ingelheim is currently seeking novel applications for its unprecedented, potent and highly selective orally bioavailable BCL6 degrader BI-1136.

Oral BCL6 degrader News Announcement

Watch the exciting success story of the launch of opnMe: Learn what issues the opnMe team had to tackle and how they overcame it…
up
60

8 April 2019

End of 2018, the opnMe core team produced a small movie which outlined the story of opnMe open innovation portal from its conception until its first successes after its launch in November 2017.

Order for free today: With BIII 890CL (crobenetine) a highly potent and selective Nav1.2 sodium channel blocker was added to opnMe.com to foster independent research and discovery
up
61

27 March 2019

The opnMe team is pleased to announce the addition of its 30th Molecule 2 Order to the Boehringer Ingelheim open innovation portal. BIII 890CL (crobenetine) is a potent, selective and highly use-dependent sodium channel blocker.

HIV Transcriptase News Announcement

With the HIV reverse transcriptase inhibitor BI-2540 we have added another molecule from our HIV pipeline to opnMe.com: Order for FREE today
up
55

18 February 2019

Now, scientists from all over world can access our molecule completely free of charge without any shipment costs to pursue further pre-clinical research independently of us.

HIV Transcriptase News Announcement

Now on opnMe.com: Boehringer Ingelheim’s strong legacy in antiviral research is shared with you! Unlock the potential of our HIV Integrase inhibitor – Order for FREE today
up
55

11 February 2019

The opnMe team is pleased to announce the addition of BI 224436 to its molecules 2 order program. Now, scientists from all over the world can access our molecule completely free of charge without any shipment costs.

HIV Integrase News Announcement